Literature DB >> 19027962

Opposite effects of high and low frequency rTMS on mood in depressed patients: relationship to baseline cerebral activity on PET.

A M Speer1, B E Benson, T K Kimbrell, E M Wassermann, M W Willis, P Herscovitch, R M Post.   

Abstract

BACKGROUND: Optimal parameters of rTMS for antidepressant efficacy in general, or within patients, have not been adequately delineated.
METHODS: Using a double-blind, sham-controlled, cross-over design, 22 adult patients with treatment refractory major depression (n=9; bipolar disorder, depressed phase) were randomized to active rTMS (20-Hz or 1-Hz) or sham rTMS conditions and given 5 rTMS treatments per week for two weeks. Repetitive TMS was administered at 100% of motor threshold for 1600 pulses over the left prefrontal cortex using a figure-eight coil. Patients initially randomized to sham rTMS were then exposed to two weeks of active rTMS with each frequency under blinded conditions. Those who received active 20-Hz and 1-Hz rTMS were crossed over to the opposite frequency for two weeks. Improvement in Hamilton Depression ratings were assessed after each two-week treatment phase. PET imaging was used to evaluate the patient's baseline absolute regional cerebral activity (blood flow and metabolism) as potential predictor of clinical response.
RESULTS: Changes in depression severity on 1-Hz and 20-Hz rTMS were inversely correlated. PET scans with baseline hypoperfusion (but not hypometabolism) were associated with better improvement on 20-Hz rTMS as predicted. LIMITATIONS: The magnitude of the clinical change with either frequency at 100% motor threshold was not robust, and larger studies with higher intensities of rTMS for longer durations of time should be explored.
CONCLUSIONS: High and low frequency rTMS exerts differential effects on depressed mood within individual subjects. The brain activity predictors and correlates of an optimal antidepressant response to rTMS remain to be better defined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027962      PMCID: PMC2779113          DOI: 10.1016/j.jad.2008.10.006

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  25 in total

Review 1.  Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies.

Authors:  Terence A Ketter; Po W Wang
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

2.  Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis.

Authors:  Tal Burt; Sarah H Lisanby; Harold A Sackeim
Journal:  Int J Neuropsychopharmacol       Date:  2002-03       Impact factor: 5.176

3.  Double-blind controlled investigation of bilateral prefrontal transcranial magnetic stimulation for the treatment of resistant major depression.

Authors:  C K Loo; P B Mitchell; V M Croker; G S Malhi; W Wen; S C Gandevia; P S Sachdev
Journal:  Psychol Med       Date:  2003-01       Impact factor: 7.723

4.  A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression.

Authors:  Paul B Fitzgerald; Jessica Benitez; Anthony de Castella; Z Jeff Daskalakis; Timothy L Brown; Jayashri Kulkarni
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

5.  Preliminary findings of uncoupling of flow and metabolism in unipolar compared with bipolar affective illness and normal controls.

Authors:  Robert T Dunn; Mark W Willis; Brenda E Benson; Jennifer D Repella; Tim A Kimbrell; Terence A Ketter; Andrew M Speer; Elizabeth A Osuch; Robert M Post
Journal:  Psychiatry Res       Date:  2005-11-30       Impact factor: 3.222

6.  Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity.

Authors:  Frank Padberg; Peter Zwanzger; Martin E Keck; Norbert Kathmann; Patrick Mikhaiel; Robin Ella; Philipp Rupprecht; Heike Thoma; Harald Hampel; Nicola Toschi; Hans-Jürgen Möller
Journal:  Neuropsychopharmacology       Date:  2002-10       Impact factor: 7.853

7.  A controlled trial of daily left prefrontal cortex TMS for treating depression.

Authors:  M S George; Z Nahas; M Molloy; A M Speer; N C Oliver; X B Li; G W Arana; S C Risch; J C Ballenger
Journal:  Biol Psychiatry       Date:  2000-11-15       Impact factor: 13.382

8.  Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial.

Authors:  David Rossini; Adelio Lucca; Raffaella Zanardi; Lorenzo Magri; Enrico Smeraldi
Journal:  Psychiatry Res       Date:  2005-10-12       Impact factor: 3.222

9.  High (15 Hz) and low (1 Hz) frequency transcranial magnetic stimulation have different acute effects on regional cerebral blood flow in depressed patients.

Authors:  C K Loo; P S Sachdev; W Haindl; W Wen; P B Mitchell; V M Croker; G S Malhi
Journal:  Psychol Med       Date:  2003-08       Impact factor: 7.723

10.  Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy.

Authors:  Ziad Nahas; F Andrew Kozel; Xingbao Li; Berry Anderson; Mark S George
Journal:  Bipolar Disord       Date:  2003-02       Impact factor: 6.744

View more
  35 in total

Review 1.  Frontocingulate dysfunction in depression: toward biomarkers of treatment response.

Authors:  Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

2.  Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Adult and Youth Populations: A Systematic Literature Review and Meta-Analysis.

Authors:  Laura E Leggett; Lesley J J Soril; Stephanie Coward; Diane L Lorenzetti; Gail MacKean; Fiona M Clement
Journal:  Prim Care Companion CNS Disord       Date:  2015-11-05

3.  Network-Guided Transcranial Magnetic Stimulation for Depression.

Authors:  Marc J Dubin; Conor Liston; Michael A Avissar; Irena Ilieva; Faith M Gunning
Journal:  Curr Behav Neurosci Rep       Date:  2017-02-07

Review 4.  Exploration and modulation of brain network interactions with noninvasive brain stimulation in combination with neuroimaging.

Authors:  Mouhsin M Shafi; M Brandon Westover; Michael D Fox; Alvaro Pascual-Leone
Journal:  Eur J Neurosci       Date:  2012-03       Impact factor: 3.386

Review 5.  Imaging TMS: antidepressant mechanisms and treatment optimization.

Authors:  Marc Dubin
Journal:  Int Rev Psychiatry       Date:  2017-02-15

Review 6.  Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials.

Authors:  Marcelo T Berlim; Frederique Van den Eynde; Z Jeff Daskalakis
Journal:  Neuropsychopharmacology       Date:  2012-11-19       Impact factor: 7.853

Review 7.  Transcranial cortical stimulation in the treatment of obsessive-compulsive disorders: efficacy studies.

Authors:  Ghassen Saba; Albert Moukheiber; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

8.  Repetitive transcranial magnetic stimulation inhibits Sirt1/MAO-A signaling in the prefrontal cortex in a rat model of depression and cortex-derived astrocytes.

Authors:  Zheng-Wu Peng; Fen Xue; Cui-Hong Zhou; Rui-Guo Zhang; Ying Wang; Ling Liu; Han-Fei Sang; Hua-Ning Wang; Qing-Rong Tan
Journal:  Mol Cell Biochem       Date:  2017-09-25       Impact factor: 3.396

9.  Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation.

Authors:  Albino J Oliveira-Maia; Daniel Press; Alvaro Pascual-Leone
Journal:  Brain Stimul       Date:  2017-03-31       Impact factor: 8.955

Review 10.  Neurostimulatory and ablative treatment options in major depressive disorder: a systematic review.

Authors:  Pablo Andrade; Lieke H M Noblesse; Yasin Temel; Linda Ackermans; Lee W Lim; Harry W M Steinbusch; Veerle Visser-Vandewalle
Journal:  Acta Neurochir (Wien)       Date:  2010-01-26       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.